Monday, April 18, 2022

COVID-19 vaccine protects kids and teens from severe illness


 News Release 18-Apr-2022
Study evaluated Pfizer-BioNTech vaccine effectiveness during the Delta and Omicron periods in children 5-18 years of age
Peer-Reviewed Publication
Ann & Robert H. Lurie Children's Hospital of Chicago


Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5–11 years by two-thirds during the Omicron period. Among adolescents ages 12–18 years who were vaccinated with a primary series of Pfizer-BioNTech vaccine, protection against COVID-19-associated hospitalization during the Omicron period was lower than during the Delta period, similar to what has been previously shown among adults. Levels of protection against critical COVID-19 requiring life-supporting interventions remained high in vaccinated adolescents during both the Delta and the Omicron periods. 



No comments:

Post a Comment